SCHEMBL30775322

SCHEMBL30775322

Fc1cncnc1N1CCCCC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.42
NPC1 O15118 2/20 0.41
PKM P14618 1/20 0.41
HTT P42858 5/20 0.41
LMNA P02545 3/20 0.41
ALOX15 P16050 2/20 0.41
AKT2 P31751 1/20 0.41
MAP3K5 Q99683 1/20 0.41
JAK3 P52333 2/20 0.40
THRB P10828 1/20 0.39
ALDH1A1 P00352 3/20 0.39
MAPK1 P28482 2/20 0.39
HPGD P15428 2/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
MAPT P10636 2/20 0.38
PRNP P04156 1/20 0.38
TSHR P16473 1/20 0.38
PPARG P37231 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30775228 0.98 TP53 (0.40) TP53NPC1PKMHTTLMNA
SCHEMBL10435174 0.83 CYP2D6 (0.39) ALOX15ALDH1A1MAPK1HPGDSMN1; SMN2
SCHEMBL30775415 0.81 KDM4E (0.58) NPC1JAK3MAPK1SMN1; SMN2RAB9A
SCHEMBL30775194 0.81 SMN1; SMN2 (0.57) PKMHTTALOX15ALDH1A1MAPK1
SCHEMBL30775287 0.81 HSD17B10 (0.42) TP53HTTLMNAALOX15ALDH1A1
SCHEMBL17364448 0.81 KDM4E (0.58) NPC1JAK3MAPK1SMN1; SMN2RAB9A
SCHEMBL31553945 0.78 MAPT (0.50) TP53NPC1PKMHTTLMNA
SCHEMBL4439434 0.77 JAK3 (0.44) TP53NPC1PKMHTTLMNA
SCHEMBL25505879 0.77 HTT (0.49) TP53NPC1PKMHTTLMNA
SCHEMBL8117744 0.74 HTT (0.46) TP53NPC1PKMHTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 US claimed
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof DONG-A ST CO., LTD. (KR) 2025-03-04 US disclosed
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof EIF2AK4, GCN1, GCGR TP53 4562/4885NPC1 89/4885PKM 2061/4885
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF EIF2AK4, GCN1, GCGR TP53 4562/4885NPC1 89/4885PKM 2061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.